Fibromyalgie chronic widespread pain Fibromyalgia
Conditions
Interventions
None listed
Sponsors
Universiteit Leiden
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: 18-65 years old female Good understanding of written and spoken Dutch Additionally for Patients: Diagnosis of fibromyalgia (provided by a rheumatologist)
Exclusion criteria
Exclusion criteria: For patients: Physical conditions other than fibromyalgia explaining pain symptoms Psychiatric conditions not related to fibromyalgia symptoms (e.g., schizophrenia) Use of painkillers different than usual dose of treatment on the day of experimentation* For healthy controls: Chronic pain complaints (>=3 months) in the past or present or a diagnosis of fibromyalgia Severe physical or psychiatric co-morbidities that may interfere with the study protocol (e.g., DSM-V diagnosis) Current pain (>=3/10 on the Numeric Rating Scale) on the day of experimentation* Use of painkillers within 24 hours before the day of experimentation* Common criteria for both groups: Pregnancy or lactation Color blindness Injuries/open wounds on the non-dominant hand or arm* Carrying a pacemaker/implanted pumps Having implanted metals on the non-dominant hand or arm Refusal to remove artificial nails, nail polish, or any other substance covering the thumbnail* Unsuccessful pressure calibration, i.e., not being able to stably distinguish relevant pressure intensities *Exclusion criteria marked with a * pertain to the day of testing. In case one or more of these criteria are met at the day of testing, the appointment will be rescheduled if possible.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| In part 1, individual susceptibility to nocebo conditioning (pain levels in conditioned trials versus control trials) will be studied as predictor of the main follow-up parameter, i.e., changes in self-reported clinical pain from baseline to follow-up. In part 2, susceptibility to nocebo conditioning will be examined and compared between patients and healthy controls. In part 3, within-group stability in susceptibility to nocebo conditioning will be examined across 1 month. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary study parameter of part 1 include individual differences in susceptibility to extinction learning as secondary predictor of pain progression. We will also explore the relation of these predictors, i.e. nocebo conditioning and extinction, to secondary follow-up parameters of fibromyalgia progression and daily symptom fluctuations. In part 2, extinction learning will be examined and compared between patients and healthy controls, and in part 3 within-group stability in extinction learning, and between-group comparisons of stability in nocebo-related learning processes (conditioning and extinction) will be examined across 1 month. | — |
Countries
Netherlands
Outcome results
None listed